Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

TRCN-1023, an experimental treatment for ALS, aims to restore UNC13A function. It is designed to improve communication between nerves and muscles. Global Phase 1/2 clinical trials are underway to ...

Reasons to be Cheerful reports that cycling improves focus in kids, especially those with ADHD, as seen in Spooner Middle School's successful Riding for Focus program.

Bocunebart's PACAP-targeting mechanism positions it as a potential first-in-class therapy in a thin pipeline of novel ...

MANILA, Philippines — The Quezon City government and pharmaceutical company Boehringer Ingelheim (Philippines) Inc. have ...

A pre-wedding video showing Pune realtor Ketan Agarwal joyfully celebrating with his fiancée Siya Goyal and her parents has ...

A road repair program designed for holistic city reconstruction was called into question by councilors Monday at a public works committee meeting in council chambers, 50 Town Square, Lima. If ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...

Beauty's next frontier isn't a product, it's brain health, with science-backed rituals reshaping skincare and a wellness ...

Don't buy a "borrowed science" NAD supplement. Discover how Niagen Bioscience’s patented NR safely and efficiently boosts ...

Spread the love“`html Attention Deficit Hyperactivity Disorder (ADHD) is a condition that affects millions of students across the globe. As students transition into high school, the challenges posed ...

The U.S. Army veteran-operated maker of advanced photonic solutions will support U.S. Army's night fighting capability ...